Condom label changes
This article was originally published in The Gray Sheet
Executive Summary
FDA will delay a final rule on new label requirements for latex condoms with spermicidal lubricant containing nonoxynol-9 in order to evaluate comments, the agency says in a final rule for those without N-9. The latter rule, slated for publication in the Nov. 10 Federal Register, simplifies previously proposed label changes and requires manufacturers to state whether the devices are latex or another material. It also requires them to update directions for use; explain latex condoms prevent pregnancy but do not completely eliminate the risk; and state that condoms reduce the risk of sexually transmitted infections such as HIV and gonorrhea but are less effective against HPV and herpes. The label changes are more direct than proposed changes, which industry had disparaged as "too complex." The final rule also gives firms an extra month to comply if their condoms are currently marketed - totaling 13 months after publication of the final rule
You may also be interested in...
Regulatory News In Brief
Stryker recall: An Oct. 24-initiated recall of 322 Stryker Custom Cranial Implant Kits is Class I, the most serious category, FDA says Dec. 24. The kits were not sterilized according to proper standards, Stryker stated, and therefore may cause serious health problems including infection, intracranial abscess, sepsis, neurological deterioration and even death. Hospitals and company reps have been notified and physicians should stop implanting the product and monitor implanted patients for signs of infection. The kits were distributed from Nov. 5, 2007, through Oct. 23, 2008. On Nov. 20, 2008, FDA sent a 1warning letter to Contract Medical Manufacturing, which makes custom implants for Stryker, for problems with its sterilization process
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.